SuanFarma-Header

SuanFarma-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Pluristem Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Post An Enquiry

Cell & Gene Therapy Manufacturing

Participation Not Confirmed

Update your events

Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study

Lead Product(s): PLX-R18

Therapeutic Area: Hematology Product Name: PLX-R18

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2020

Details:

The Phase I multi-center, open-label, 3 cohort dose-escalating study is evaluating the safety of intramuscular (IM) injections of PLX-R18 cells in 20 subjects, with incomplete hematopoietic recovery persisting for at least 3 months after HCT.